Order results by:
| Issue | Title | |
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... Objective: to evaluate the pharmacoeconomic efficiency of atezolizumab (inhibitor of programmed ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... Objective: to evaluate the pharmacoeconomic efficacy of “atezolizumab + bevacizumab + paclitaxel ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... traditional platinum-containing chemotherapy with inhibitors of programmed death-ligand 1 (PD-L1) atezolizumab ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... cancer (NSCLC). Materials and methods. The calculations included the direct costs of the healthcare ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| "... neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| "... Treatment of patients with non-small-cell lung cancer (NSCLC) is one of important problems ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS | Abstract similar documents |
| A. Yu. Kulikov, V. G. Serpik | ||
| "... Pharmacoeconomic study of treatment primary open-angle glaucoma with carbonic anhydrise inhibitors ..." | ||
| Vol 16, No 4 (2023) | Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma | Abstract similar documents |
| S. K. Zyryanov, K. V. Orlova | ||
| "... with prolgolimab as the first line and combination therapy with BRAF/MEK inhibitors as the second line versus ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS | Abstract similar documents |
| M. V. Protsenko | ||
| "... of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib and abemaciclib ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| Vol 6, No 2 (2013) | COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... performed cost-effectiveness analysis on the basis of two tyrosine kinase inhibitors in Russian Federation ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... -effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian ..." | ||
| Vol 8, No 2 (2015) | SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS | Abstract similar documents |
| Georgii Rubenovich Khachatryan, Vladislav Sergeevich Dombrovskii | ||
| "... (RF). Dipeptidyl peptidase-4 (DPP-4) inhibitors alogliptin, vildagliptin, linagliptin, saxagliptin ..." | ||
| Vol 16, No 2 (2023) | Key principles of drug therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| A. V. Zhuravlev, O. I. Knysh | ||
| "... , the most significant is the prescription of tyrosine kinase inhibitors (TKIs), since they have pronounced ..." | ||
| Vol 15, No 1 (2022) | Efficacy of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation: a systematic literature review update | Abstract similar documents |
| V. D. Sokolova, N. A. Sableva, V. V. Mladov, D. G. Tolkacheva | ||
| "... trials (RCTs) on a new interleukin (IL) 23 inhibitor registered in the Russian Federation – risankizumab ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... and various TNF-α inhibitors) in adult patients with moderate to severe active ulcerative colitis (UC ..." | ||
| Vol 16, No 3 (2023) | Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy | Abstract similar documents |
| O. A. Shavlovskaya, О. А. Gromova, A. Yu. Kochish, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova | ||
| "... metalloproteinase inhibitors, inhibitors of pro-inflammatory interleukins, etc.). The main delivery systems of drugs ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... , while the most expensive first-line regimens included a protease inhibitors class drug as the third ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... of protease inhibitors with adult patients with Type 1 HIV infection (HIV-1) that have no experience ..." | ||
| Vol 11, No 1 (2018) | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics | Abstract similar documents |
| Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko | ||
| "... than 60% of fluoroquinolones, 3d generation cephalosporins and inhibitor-protected penicillin ..." | ||
| Vol 15, No 1 (2022) | The analysis of the consumption level of antihypertensive drugs and statins in a retail pharmacy of the Samara Region in 2015–2020 | Abstract similar documents |
| I. K. Petrukhina, P. A. Lebedev, E. P. Gladunova, T. K. Ryazanova, A. A. Garanin, P. R. Blinkova | ||
| "... , angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β ..." | ||
| Vol 16, No 3 (2023) | Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin | ||
| "... with angiotensin-converting enzyme inhibitors, beta-blockers, and mineralocorticoid-receptor antagonists ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... ) inhibitors’ prescriptions. In addition, alternative scenarios were modeled that included prescription ..." | ||
| Vol 14, No 4 (2021) | Peptides of Laennec® preparation that contribute to the elimination of endotheliopathy | Abstract similar documents |
| I. Yu. Torshin, О. А. Gromova, V. G. Zgoda, А. G. Chuchalin, V. А. Maksimov, О. V. Tikhonova | ||
| "... sequencing of the isolated peptides. Results. The preparation contains peptides-inhibitors of specific target ..." | ||
| Vol 16, No 4 (2023) | Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. N. Gromov, O. V. Tikhonova | ||
| "... adrenomedullins, inhibitor peptides of a number of kinases (FYN, SHH, WNK1/4, SGK1, IRAK4, ROCK1/2) and fibrogenic ..." | ||
| Vol 15, No 3 (2022) | Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... (dialysis or transplantation). Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which ..." | ||
| Vol 9, No 3 (2016) | DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY | Abstract similar documents |
| M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov | ||
| "... used in 92.86% of the regions), and among hormonal antineoplastic drugs were aromatase inhibitors ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... with psoriatic arthritis (PsA) with a Russian interleukin- 17А inhibitor netakimab in comparison with other ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... . In the grope of combinations of angiotensin-converting enzyme inhibitors with diuretics/calcium channel ..." | ||
| Vol 18, No 1 (2025) | Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis | Abstract similar documents |
| S. A. Doktorova, Yu. Yu. Grabovetskaya, A. V. Zuev, J. N. Aksenova-Sorokhtei, V. V. Rafalskiy | ||
| "... identified a high frequency of prescriptions for proton pump inhibitors, GCs, and cholecalciferol ..." | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic study of active psoriatic arthritis treatment | Abstract similar documents |
| A. V. Rudakova, Т. V. Korotaeva | ||
| "... with psoriatic arthritis (PsA) using netakimab, a Russian interleukin-17 inhibitor, in comparison with other ..." | ||
| Vol 14, No 1 (2021) | Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 | Abstract similar documents |
| O. V. Zhukova, A. L. Khokhlov | ||
| "... of clinical and economic constituents of the application of an IL-6 inhibitor tocilizumab and systemic ..." | ||
| 1 - 36 of 36 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
